Evidence map›Paper›PMID 34390285›Full record

ArticlePharmacoepidemiology and drug safety2021

Association between inhaled corticosteroid use and COVID-19 outcomes.

Anders Husby, Anton Pottegård, Anders Hviid

Open access · bronzeAbstract read
In one paragraph

Article in Pharmacoepidemiology and drug safety, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Inhaled corticosteroids for the treatment of COVID-19.European respiratory review : an official journal of the European Respiratory Society · 2022
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Anders HusbyDepartment of Epidemiology Research, Statens Serum Institut, Copenhagen S, Denmark.ORCID https://orcid.org/0000-0002-7634-8455
Anton PottegårdClinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.ORCID https://orcid.org/0000-0001-9314-5679
Anders HviidDepartment of Epidemiology Research, Statens Serum Institut, Copenhagen S, Denmark.ORCID https://orcid.org/0000-0002-7509-9127
Statens Serum Institut · DKUniversity of Southern Denmark · DK

Funding

Novo Nordisk Foundation
6 · The paper itself

Abstract

backgroundRecent evidence has established a beneficial effect of systemic corticosteroids for treatment of moderate-to-severe COVID-19.

objectiveTo determine if inhaled corticosteroid use is associated with COVID-19 outcomes.

methodsIn a nationwide cohort of hospitalized SARS-CoV-2 test-positive individuals in Denmark, we estimated the 30-day hazard ratio of intensive care unit (ICU) admission or death among users of inhaled corticosteroids (ICS) compared with users of bronchodilators (β

resultsAmong 6267 hospitalized SARS-CoV-2 patients, 614 (9.8%) were admitted to ICU and 677 (10.8%) died within 30 days. ICS use was associated with a hazard ratio of 1.09 (95% CI [CI], 0.67 to 1.79) for ICU admission and 0.78 (95% CI, 0.56 to 1.11) for death compared with bronchodilator use. Compared with no ICS use overall, the hazard ratio of ICU admission or death was 1.17 (95% CI, 0.87-1.59) and 1.02 (95% CI, 0.78-1.32), respectively. Among 10 279 hospitalized influenza patients, of which 951 (9.2%) were admitted to ICU and 1275 (12.4%) died, the hazard ratios were 1.43 (95% CI, 0.89-2.30) and 1.11 (95% CI, 0.85-1.46) for ICU admission, and 0.80 (95% CI, 0.63-1.01) and 1.03 (95% CI, 0.87-1.22) for death compared with bronchodilator use and no ICS use overall, respectively.

conclusionOur results do not support an effect of inhaled corticosteroid use on COVID-19 outcomes, however we can only rule out moderate-to-large reduced or increased risks. STUDY REGISTRATION: The study was pre-registered at encepp.eu (EUPAS35897).

Indexed as

COVID-19Adrenal Cortex HormonesHospitalizationHumansIntensive Care UnitsSARS-CoV-2Adrenal Cortex Hormonescohort studyCOVID-19inhaled corticosteroidspharmacoepidemiology

Identifiers

PMID34390285
PMCPMC8441753
OpenAlexW3188143639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.